Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014		Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 653,120		$ 477,239
Trade accounts receivable, less allowance for doubtful accounts (2014 – $1,578; 2013 – $1,614)	383,325		446,864
Other accounts receivable	41,261		45,094
Inventories	367,911	[1]	436,049
Other current assets	62,690		77,669
Total current assets	1,508,307		1,482,915
Property, plant and equipment, at cost	2,623,271		2,972,084
Less accumulated depreciation and amortization	1,392,997		1,615,015
Net property, plant and equipment	1,230,274		1,357,069
Investments	196,512		212,178
Other assets	160,291		160,229
Goodwill	251,964		284,203
Other intangibles, net of amortization	46,118		88,203
Total assets	3,393,466		3,584,797
Current liabilities:
Accounts payable	205,809		194,064
Accrued expenses	214,243		190,533
Current portion of long-term debt	368,268		24,554
Dividends payable	21,275		19,197
Income taxes payable	3,115		8,015
Total current liabilities	812,710		436,363
Long-term debt	684,107		1,054,310
Postretirement benefits	52,872		53,903
Pension benefits	67,659		57,647
Other noncurrent liabilities	93,732		110,610
Deferred income taxes	95,115		129,188
Commitments and contingencies (Note 8)
Albemarle Corporation shareholders’ equity:
Common stock, $.01 par value, issued and outstanding – 78,249 in 2014 and 80,053 in 2013	782		801
Additional paid-in capital	6,992		9,957
Accumulated other comprehensive (loss) income	(1,651)		116,245
Retained earnings	1,450,618		1,500,358
Total Albemarle Corporation shareholders’ equity	1,456,741		1,627,361
Noncontrolling interests	130,530		115,415
Total equity	1,587,271		1,742,776
Total liabilities and equity	$ 3,393,466		$ 3,584,797

[1] Decrease in Total inventories is primarily related to the sale of our antioxidant, ibuprofen and propofol businesses and assets which closed on September 1, 2014.